Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
Phase 2
Terminated
- Conditions
- Alzheimer's Disease
- Interventions
- Registration Number
- NCT02051764
- Lead Sponsor
- Avid Radiopharmaceuticals
- Brief Summary
This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- Have a previous 18F-AV-1451 brain scan
- Can tolerate up to two Positron Emission Tomography (PET) imaging sessions and a Magnetic Resonance Imaging (MRI) scan
- Ability to provide informed consent
Exclusion Criteria
- Current clinically significant psychiatric disease
- Are claustrophobic
- Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes
- Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
- Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
- Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Follow-up Flortaucipir PET Scan Brain PET Scan - Follow-up Flortaucipir PET Scan Flortaucipir F18 - Follow-up Flortaucipir PET Scan Florbetapir F 18 -
- Primary Outcome Measures
Name Time Method Change in Tau Deposition baseline scan and at least 6 months after baseline scan Rate of tau deposition change as measured by flortaucipir standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Hoag Memorial Hospital
🇺🇸Newport Beach, California, United States
UC Irvine Medical Center
🇺🇸Orange, California, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Center for Clinical Imaging Research, Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States